Viatris launches first generic of AstraZeneca asthma drug Symbicort
jsolie         
Viatris (NASDAQ:VTRS) has launched a generic version of AstraZeneca's asthma and chronic obstructive pulmonary disease inhaler Symbicort (budesonide and formoterol) under the name Breyna.
The drug is available in 80 mcg/4.5 mcg and 160 mcg/4.5 mcg dosage strengths.
Breyna is the first Symbicort generic to hit the market.
In Q2, Symbicort brought in $600M for AstraZeneca (NASDAQ:AZN).

More on ViatrisÂ 

Viatris: Currently Appealing Only To Income-Focused Investors
Viatris: Developing Into A Fantastic Investment Opportunity